The human genome contains numerous genes whose protein products are unknown in terms of structure, interaction partner, expression, and function. To unravel the function of these orphan genes, it is of particular value to isolate native forms of protein and peptide products derived from these genes. From human blood ultrafiltrate, we characterized a novel gene-encoded, cysteine-rich, and cationic peptide that we termed liver-expressed antimicrobial peptide 2 (LEAP-2). We identified several circulating forms of LEAP-2 differing in their amino-terminal length, all containing a core structure with two disulfide bonds formed by cysteine residues in relative 1-3 and 2-4 positions. Molecular cloning of the cDNA showed that LEAP-2 is synthesized as a 77-residue precursor, which is predominantly expressed in the liver and highly conserved among mammals. This makes it a unique peptide that does not exhibit similarity with any known human peptide regarding its primary structure, disulfide motif, and expression. Analysis of the LEAP-2 gene resulted in the identification of an alternative promoter and at least four different splicing variants, with the two dominating transcripts being tissue-specifically expressed. The largest native LEAP-2 form of 40 amino acid residues is generated from the precursor at a putative cleavage site for a furin-like endoprotease. In contrast to smaller LEAP-2 variants, this peptide exhibited dose-dependent antimicrobial activity against selected microbial model organisms. LEAP-2 shares some characteristic properties with classic peptide hormones and it is expected that the isolation of this novel peptide will help to unravel its physiological role.Keywords: Alternative splicing; antimicrobial activity; disulfide bonds; hemofiltrate; liver; peptide; secretion As a consequence of the efforts to sequence and assemble the human genome (Lander et al. 2001;Venter et al. 2001), the systematic analysis of peptides and proteins as the functional gene products produced by a given cell population or tissue under defined conditions is considered to be the next milestone in molecular biology. The estimated number of genes is unexpectedly low, and the number of biologically active peptides and proteins cannot be deduced from these data because of events such as alternative splicing of mRNA precursors, usage of alternative gene promoters, pseudogenes, and alternatively processed proteins. The number of proteins is therefore estimated to be two to three orders of magnitude higher than the number of ∼40,000 genes annotated in the human genome (Harrison et al. 2002;Rappsilber and Mann 2002). Therefore, the mass-spectrometric identification of a gene product in proteomics or, even better, the isolation of novel proteins and peptides followed by a struc-5 Reprint requests to: Knut Adermann, IPF PharmaCeuticals GmbH, Hannover, Germany; e-mail: knut.adermann@ipf-pharmaceuticals.de; fax: 49 (0) 511 5466 132.Abbreviations: CFU, colony-forming unit; ESIMS, electrospray ionization mass spectrometry; LEAP, liver...

No abstract